Correction to: Scientific Reports https://doi.org/10.1038/s41598-020-60437-0, published online 27 February 2020
This Article contains a typographical error in the Introduction where the following is repeated twice:
“A single response profile, such as pseudo-progression, is observed under CPIs7. Among these typically-related response profiles under CPIs is hyperprogressive disease (HPD), which was defined as an unanticipated and paradoxical acceleration of the tumor growth7,8. The incidence of HPD is variable according to the way it is defined and ranges between 4 and 29%7. Though such acceleration of the tumor growth kinetic was also observed with other agents (chemotherapy9, tyrosine kinase inhibitors10), the intensity and the frequency of the phenomenon appears to be higher with checkpoint inhibitors used alone7.”
Additionally, Table 4 contains an error where the labels for ‘Risk Group’ and ‘Hyperprogressive Disease’ are swapped. The correct Table 4 appears below.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Refae, S., Gal, J., Brest, P. et al. Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Sci Rep 10, 9857 (2020). https://doi.org/10.1038/s41598-020-66841-w
Published:
DOI: https://doi.org/10.1038/s41598-020-66841-w
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
